Stock listing

SIX Swiss:MOLN Molecular Partners AG Aktie

Home listing (SIX Swiss) of Molecular Partners AG

Follow Molecular Partners AG into a list and get an email when it puts out news.

Share price · SIX:MOLN

3.15 CHF +0.07 (+2.3%)

Close on Oct 15, 2026

Molecular Partners AG logo
Ticker
SIX Swiss:MOLN
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
SIX Swiss
Currency
CHF

What changed lately

Calls

Replays

  • Molecular Partners (SIX Swiss: MOLN) Q2 2024 Earnings Call

    Tue, Aug 27, 2024 · 8:00 AM ET

    Watch Transcript

  • Molecular Partners (SIX Swiss: MOLN) Q4 2023 Earnings Call

    Fri, Mar 15, 2024 · 8:00 AM ET

    Watch Transcript

  • Molecular Partners (SIX Swiss: MOLN) Q4 2022 Earnings Call

    Fri, Mar 10, 2023 · 11:00 AM ET

    Watch Transcript

Latest news

Molecular Partners Reports H1 2026 Financial Results and Corporate Highlights: DLL3 Radiotherapy MP0712 Successfully Advancing to Higher Dose Level in Phase 1/2a Study

Aug 25, 2026

Molecular Partners Announces Clinical Progress in Phase 2 TACTIC Combination Trial of MP0317 for Patients with Cholangiocarcinoma

Jul 16, 2026

Molecular Partners Showcases Bispecific Radio-DARPins at Gordon Research Conference

Jul 15, 2026

Molecular Partners Updates on Clinical Progress Across Expanding Pipeline of DARPin Radiotherapeutics

Jul 6, 2026

Molecular Partners and Orano Med Announce First Patients Dosed in Phase 1/2a Trial of DLL3 Radio-DARPin MP0712

Jul 2, 2026

Molecular Partners Holds Presentations at ASCO and SNMMI 2026 on DLL3-Targeting Radio-DARPin MP0712, Now Dosing Patients in Phase 1

May 30, 2026

Molecular Partners to Present at TD Cowen’s 7th Annual Oncology Innovation Summit

May 26, 2026

Molecular Partners Reports Financial Results and Highlights for Q1 2026, with Clinical Studies Initiated on MP0712 and MP0317

May 12, 2026

Molecular Partners to hold oral presentations on DLL3-targeting Radio-DARPin candidate MP0712 at multiple upcoming scientific conferences

May 4, 2026

Molecular Partners publishes Phase 1 MP0317 data in Nature Cancer demonstrating tumor-localized CD40 activation and tumor microenvironment remodeling

May 1, 2026

All Molecular Partners AG news

Decks

Molecular Partners AG on 6ix

Sector
Health care
Industry
Biotechnology
News releases
28 in the last 12 months · 41 in all · newest Aug 25, 2026 · oldest 2025
Calls
3 calls with a replay · 3 with a transcript · latest Aug 27, 2024
Decks
5 decks · latest Aug 25, 2026

Where Molecular Partners AG is listed

ListingExchangeCountryCurrency
SIX Swiss:MOLN · Home listing · This pageSIX SwissSwitzerlandCHF
NASDAQ:MOLNNASDAQUnited StatesUSD
Lang & Schwarz:A12DEHLang & SchwarzGermanyEUR
LS Exchange:A12DEHLS ExchangeGermanyEUR
OTC:MLLCFOTCUnited StatesUSD
LSE:0QXXLSEUnited KingdomCHF
gettex:6MLgettexGermanyEUR
BX Swiss:6MLBX SwissSwitzerlandCHF
gettex:6ML0gettexGermanyEUR
Aquis:MOLNZAquisUnited KingdomCHF
BOATS:MOLNBOATSUnited StatesUSD
Dusseldorf:6ML0DusseldorfGermanyEUR
Frankfurt:6MLFrankfurtGermanyEUR
Frankfurt:6ML0FrankfurtGermanyEUR
Hamburg:6MLHamburgGermanyEUR
Lang & Schwarz:A3CSB5Lang & SchwarzGermanyEUR
LS Exchange:A3CSB5LS ExchangeGermanyEUR
Munich:6MLMunichGermanyEUR
Munich:6ML0MunichGermanyEUR
Stuttgart:6MLStuttgartGermanyEUR
Stuttgart:6ML0StuttgartGermanyEUR
Tradegate:6ML0TradegateGermanyEUR
Turquoise:MOLNZTurquoiseUnited KingdomCHF

Log in to ask 6ix AI your own questions about Molecular Partners AG.